--- title: "BriaCell Therapeutics (BCT) stock: news and investor profile" url: "https://aibio.space/companies/briacell-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BriaCell Therapeutics Corp (TSX: BCT), Canada. The directory classifies it as Biotechnology. Listing facts, related biotech companies and news on aibio.space." --- BCT BriaCell Therapeutics Corp TSX · Canada # BriaCell Therapeutics (BCT) news Listings · 2025-08-26 ## [BriaCell plans 1-for-10 share consolidation to meet Nasdaq listing rules](https://aibio.space/news/briacell-plans-1-10-share-consolidation-meet-nasdaq-listing-rules/) BriaCell's board approved a one-for-ten share consolidation to keep its Nasdaq listing, expected to take effect August 25, 2025, subject to approval from Nasdaq and the Toronto Stock Exchange. ## Latest BriaCell Therapeutics news 1. 2025-02-13 Listings [BriaCell Therapeutics regains compliance with Nasdaq minimum bid price requirement](https://aibio.space/news/briacell-therapeutics-regains-compliance-nasdaq-minimum-bid-price/) Nasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00. ## BriaCell Therapeutics at a glance - **Ticker**: BCT - **Listing**: TSX - **Country**: Canada - **Cash, Jul 31, 2026**: $20.5 million ### Related companies - [ZENITH CAPITAL CORPORATION](https://aibio.space/companies/zenith-capital/) OTC: ZHCLF - [Quantum Biopharma](https://aibio.space/companies/quantum-biopharma/) NASDAQ: QNTM - [Eupraxia Pharmaceuticals](https://aibio.space/companies/eupraxia-pharmaceuticals/) TSX: EPRX - [Onco-Innovations](https://aibio.space/companies/onco-innovations/) NEO: ONCO - [Avicanna](https://aibio.space/companies/avicanna/) TSX: AVCN - [NanoSphere Health Sciences](https://aibio.space/companies/nanosphere-health-sciences/) CSE: NSHS.X - [Medicus Pharma](https://aibio.space/companies/medicus-pharma/) NASDAQ: MDCX - [Rapid Dose Therapeutics](https://aibio.space/companies/rapid-dose-therapeutics/) CSE: DOSE ### Also on TSX - [Helix BioPharma](https://aibio.space/companies/helix-biopharma/) HBP - [Apotex Health](https://aibio.space/companies/apotex-health/) APTX - [Eupraxia Pharmaceuticals](https://aibio.space/companies/eupraxia-pharmaceuticals/) EPRX - [HLS Therapeutics](https://aibio.space/companies/hls-therapeutics/) HLS - [Satellos Bioscience](https://aibio.space/companies/satellos-bioscience/) MSCL - [Cipher Pharmaceuticals](https://aibio.space/companies/cipher-pharmaceuticals/) CPH ## What BriaCell Therapeutics does BriaCell Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer. Its lead candidate, Bria-IMT, is being advanced in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer, and it is under Fast Track Designation from the U.S. Food and Drug Administration. The company reports median overall survival of 13.3 months for the Phase 3 sequence in its metastatic breast cancer patients and 16.6 months for Phase 2 patients treated with the Phase 3 formulation since 2022. Incyte Corporation manufactures Retifanlimab, an anti-PD1 antibody. BriaCell is also running a Phase 1/2 study of Bria-OTS, a personalized off-the-shelf immunotherapy, in metastatic breast cancer, and is developing its advanced form, Bria-OTS+, as a platform for numerous types of cancer. The FDA has permitted Phase 1/2a clinical studies of Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, with open Investigational New Drug applications for both. The company is also developing Bria-OVA+ for ovarian cancer and Bria-MEL+, a personalized whole cell melanoma immunotherapy vaccine candidate. | Product or program | What it is | Stage | |---|---|---| | Bria-IMT | Targeted immunotherapy combined with Retifanlimab for metastatic breast cancer | Pivotal Phase 3 study | | Bria-OTS | Personalized off-the-shelf immunotherapy for metastatic breast cancer | Phase 1/2 | | Bria-OTS+ | Advanced form of Bria-OTS as a platform for numerous cancer types | In development | | Bria-BRES+ | Immunotherapy for breast cancer | Phase 1/2a studies permitted by FDA | | Bria-PROS+ | Immunotherapy for prostate cancer | Phase 1/2a studies permitted by FDA | | Bria-MEL+ | Personalized whole cell melanoma immunotherapy vaccine candidate | Advancing toward clinical development | Summarised from the company's [10-K filed Oct 28, 2026](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/form10-k.htm). ## BriaCell Therapeutics annual financials | Line | FY ended Jul 31, 2026 | FY ended Jul 31, 2025 | |---|---|---| | Research and development | [$29.2 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | [$21.3 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | | Net income (loss) | [-$34.9 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | [-$26.3 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | | Cash from operations | [-$28.7 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | [-$28.2 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | | Cash and equivalents | [$9.9 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | [$10.5 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | | Short-term investments | [$10.7 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | [$7.4 million](https://www.sec.gov/Archives/edgar/data/1610820/000149315226049041/) | Latest balance sheet, Jul 31, 2026 (10-K): cash and equivalents $9.9 million, plus short-term investments of $10.7 million, $20.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BriaCell Therapeutics What is the ticker symbol of BriaCell Therapeutics? BriaCell Therapeutics Corp trades under the ticker BCT on TSX. Where is BriaCell Therapeutics listed? BriaCell Therapeutics Corp is listed on TSX. Our directory also records these other listings: GETTEX:8BT; NASDAQ:BCTX; NEO:BCT. What is the SEC CIK of BriaCell Therapeutics? The SEC Central Index Key (CIK) for BriaCell Therapeutics Corp is 1610820. Its filings are on SEC EDGAR. How many shares does BriaCell Therapeutics have outstanding? 8,699,787 shares as of 2026-06-09, per the cover page of its 10-Q filed 2026-06-09. Which country or territory is BriaCell Therapeutics listed under? Our directory records BriaCell Therapeutics Corp under Canada. What does BriaCell Therapeutics do? Our directory classifies BriaCell Therapeutics Corp as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of BriaCell Therapeutics? The ISIN recorded for BriaCell Therapeutics Corp is CA1079303071. Does aibio.space cover BriaCell Therapeutics? aibio.space lists BriaCell Therapeutics Corp among 2,820 public biotech companies and publishes its news here as stories appear. Where is BriaCell Therapeutics incorporated? SEC records list its state or country of incorporation as A1. What does BriaCell Therapeutics develop? BriaCell Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer. Its lead candidate, Bria-IMT, is being advanced in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer, and it is under Fast Track Designation from the U.S. Food and Drug Administration. What is Bria-IMT from BriaCell Therapeutics? Bria-IMT: Targeted immunotherapy combined with Retifanlimab for metastatic breast cancer Stage: Pivotal Phase 3 study. What is Bria-OTS from BriaCell Therapeutics? Bria-OTS: Personalized off-the-shelf immunotherapy for metastatic breast cancer Stage: Phase 1/2. Is BriaCell Therapeutics profitable? BriaCell Therapeutics Corp reported a net loss of $34.9 million for the fiscal year ended Jul 31, 2026, and used $28.7 million of cash in operations, per its annual report to the SEC. How much does BriaCell Therapeutics spend on research and development? $29.2 million in the fiscal year ended Jul 31, 2026, per its annual report. How much cash does BriaCell Therapeutics have? $20.5 million in cash and short-term investments at Jul 31, 2026, per its 10-K. ## Investor discussion: BriaCell Therapeutics Members talk about BriaCell Therapeutics (BCT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BriaCell Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315226026759/form424b5.htm) 2. 2026-01-14 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315226002258/form424b4.htm) 3. 2025-12-23 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315225028916/forms-1.htm) 4. 2025-12-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315225025469/ex99-1.htm) 5. 2025-10-16 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315225018212/form10-k.htm) 6. 2025-08-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1610820/000164117225025438/ex99-1.htm) 7. 2025-07-08 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1610820/000164117225018193/forms-1.htm) 8. 2025-04-22 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1610820/000164117225005677/forms-1.htm) 9. 2025-02-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315225006419/form8-k.htm) 10. 2025-02-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315225005204/form8-k.htm) 11. 2025-01-28 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315225003977/ex99-1.htm) 12. 2025-01-03 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315225000282/ex99-1.htm) 13. 2024-12-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315224049661/form424b5.htm) 14. 2024-11-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1610820/000149315224043322/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TSX:BCT on TradingView](https://www.tradingview.com/symbols/TSX-BCT/). ## SEC filings and registration - **SEC name**: BriaCell Therapeutics Corp. - **CIK**: 1610820 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq) - **State or country of incorporation**: A1 - **Fiscal year ends**: July 31 - **Filer category**:
Emerging growth company - **Business address**: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, British Columbia, Canada, V7T 2X1 - **Phone**: (604) 921-1810 - **Shares outstanding**: 8,699,787 as of 2026-06-09 (10-Q filed 2026-06-09) - **Former names**: Ansell Capital Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/form8-k.htm) filed 2026-06-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1610820/000149315226027928/form10-q.htm) filed 2026-06-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1610820/000149315226026953/form8-k.htm) filed 2026-06-03 - [424B5](https://www.sec.gov/Archives/edgar/data/1610820/000149315226026759/form424b5.htm) filed 2026-06-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1610820/000149315226014156/form8-k.htm) filed 2026-03-31 - [10-Q](https://www.sec.gov/Archives/edgar/data/1610820/000149315226009557/form10-q.htm) filed 2026-03-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1610820/000149315226009382/form8-k.htm) filed 2026-03-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1610820/000149315226007587/form8-k.htm) filed 2026-02-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001610820), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BriaCell Therapeutics Corp is a public biotech or pharmaceutical company listed on TSX under the ticker BCT, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BriaCell Therapeutics Corp - **Ticker**: BCT - **Listing**: TSX - **Country or territory**: Canada - **Business scope**: Biotechnology - **ISIN**: CA1079303071 - **Other listed symbols**: GETTEX:8BT; NASDAQ:BCTX; NEO:BCT - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/TSX-BCT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/briacell-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BriaCell Therapeutics (BCT) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/briacell-therapeutics/